A

Adelaide Eye and Retina Centre | Adelaide, South Australia

Research site

(Unclaimed)

Location

18 North Terrace, Adelaide, South Australia, Australia

Site insights

Top conditions

Top treatments

KHK4951

BI 765128

Lampalizumab

Dexamethasone

EXN407

Aflibercept

JNJ-81201887

IBE-814

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting

Macular Edema Secondary to Retinal Vein Occlusion

Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

Drug: Sham

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling

Diabetic Macular Edema (DME)

Drug: KHK4951

Drug: Aflibercept Injection

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling

Neovascular Age-Related Macular Degeneration (nAMD)

Drug: Aflibercept Injection

Drug: KHK4951

Trial sponsors

E

R

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms